This trial is testing a new drug, pralsetinib, to see if it is safe and effective in treating medullary thyroid cancer, RET-altered non-small cell lung cancer, and other RET-altered solid tumors.
8 Primary · 30 Secondary · Reporting Duration: Approximately every 8 weeks or 16 weeks based on the treatment cycle (Up to approximately 84 months)
Experimental Treatment
589 Total Participants · 2 Treatment Groups
Primary Treatment: pralsetinib (BLU-667) · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: